moclobemide has been researched along with Aphasia in 2 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Aphasia: A cognitive disorder marked by an impaired ability to comprehend or express language in its written or spoken form. This condition is caused by diseases which affect the language areas of the dominant hemisphere. Clinical features are used to classify the various subtypes of this condition. General categories include receptive, expressive, and mixed forms of aphasia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomised 90 acute stroke patients with aphasia to either 600 mg moclobemide or placebo daily for 6 months, within 3 weeks of the onset of stroke." | 9.11 | Long-term antidepressant treatment with moclobemide for aphasia in acute stroke patients: a randomised, double-blind, placebo-controlled study. ( Hellblom, A; Kahan, T; Laska, AC; Murray, V; von Arbin, M, 2005) |
| "We randomised 90 acute stroke patients with aphasia to either 600 mg moclobemide or placebo daily for 6 months, within 3 weeks of the onset of stroke." | 5.11 | Long-term antidepressant treatment with moclobemide for aphasia in acute stroke patients: a randomised, double-blind, placebo-controlled study. ( Hellblom, A; Kahan, T; Laska, AC; Murray, V; von Arbin, M, 2005) |
| "To compare standardized and functional aphasia tests in patients after acute stroke." | 2.73 | Clinical and prognostic properties of standardized and functional aphasia assessments. ( Bartfai, A; Hellblom, A; Kahan, T; Laska, AC; Murray, V, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laska, AC | 2 |
| von Arbin, M | 1 |
| Kahan, T | 2 |
| Hellblom, A | 2 |
| Murray, V | 2 |
| Bartfai, A | 1 |
2 trials available for moclobemide and Aphasia
| Article | Year |
|---|---|
Long-term antidepressant treatment with moclobemide for aphasia in acute stroke patients: a randomised, double-blind, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Aphasia; Double-Blind Method; Drug Administration Schedule; Female; Follow- | 2005 |
Clinical and prognostic properties of standardized and functional aphasia assessments.
Topics: Antidepressive Agents; Aphasia; Double-Blind Method; Follow-Up Studies; Humans; Moclobemide; Monoami | 2007 |